826 Results for "

invasion.

" in MedChemExpress (MCE) Product Catalog:

Products (826)

Sort by :

Categories

By Targets

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

Atorvastatin

76 Publications Verification

Cat. No.: HY-B0589

CAS No.: 134523-00-5

Target:

HMG-CoA Reductase (HMGCR) Autophagy

Research Areas:

Metabolic Disease Inflammation/Immunology Cancer

Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Atorvastatin hemicalcium salt

76 Publications Verification

Cat. No.: HY-17379

CAS No.: 134523-03-8

Synonyms: CI-981; Atorvastatin hemicalcium

Target:

HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis

Research Areas:

Metabolic Disease Inflammation/Immunology Cancer

Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, with blood-brain barrier permeability. Atorvastatin hemicalcium salt has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Trastuzumab (anti-HER2)

75 Cited Publications

Cat. No.: HY-P9907A

CAS No.: 180288-69-1

Synonyms: Anti-Human HER2, Humanized Antibody (anti-HER2)

Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Atorvastatin sodium

74 Cited Publications

Cat. No.: HY-108257

CAS No.: 134523-01-6

Purity: 99.76%

Target:

HMG-CoA Reductase (HMGCR) Autophagy

Research Areas:

Metabolic Disease Inflammation/Immunology

Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Atorvastatin hemicalcium trihydrate

74 Cited Publications

Cat. No.: HY-B0589E

CAS No.: 344920-08-7

Target:

HMG-CoA Reductase (HMGCR) Autophagy

Research Areas:

Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer

Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Bemcentinib

70 Cited Publications

Cat. No.: HY-15150

CAS No.: 1037624-75-1

Purity: 99.92%

Synonyms: R428; BGB324

Target:

TAM Receptor

Research Areas:

Cancer

Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Compare